Under the agreement, NovaRhythm obtains exclusive global rights to progress the molecule through IND-enabling studies, clinical development and commercialization, with a primary objective of ...

Medtronic (NYSE:MDT) today announced CE mark approval and the first commercial European implants for its OmniaSecure system.

Electrical signals tell the heart to contract, but when the signals form spiral waves, they can lead to dangerous cardiac events like tachycardia and fibrillation. Researchers are bringing a new ...

The cardiac myosin inhibitor gets a big win in the SCOUT-HCM trial ...

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, received U.S. Food and Drug Administration (FDA) ...

The cases highlight the effectiveness of rapid coordination between frontline healthcare facilities and specialised hospitals ...

Medtronic snagged FDA approval for an expanded indication for its OmniaSecure defibrillation lead. Check out why this tiny ...

New research from a multi-institutional team, published in Nature Cardiovascular Research, reveals that heart failure and ...

Medtronic announced today that it received FDA approval for an expanded indication for its OmniaSecure defibrillation lead.

Bayer wins EU nod to expand Kerendia's use in heart failure, backed by strong phase III data, boosting a key drug driving growth and portfolio momentum.

In stabilized heart attack survivors without heart failure or left ventricular (LV) systolic dysfunction, stopping the ...

BACKGROUND: Premature atrial contractions (PACs) are independently associated with atrial fibrillation, stroke, and heart ...